Limits...
Insulin-like growth factor system in cancer: novel targeted therapies.

Brahmkhatri VP, Prasanna C, Atreya HS - Biomed Res Int (2015)

Bottom Line: These effects depend on the bioavailability of IGFs, which is regulated by IGF binding proteins (IGFBPs).We have attempted to expand the general viewpoint on IGF-1R, its inhibitors, potential limitations of IGF-1R, antibodies and tyrosine kinase inhibitors, and IGFBP actions.This can lead to the development of novel cancer therapies.

View Article: PubMed Central - PubMed

Affiliation: NMR Research Centre, Indian Institute of Science, Bangalore 560012, India.

ABSTRACT
Insulin-like growth factors (IGFs) are essential for growth and survival that suppress apoptosis and promote cell cycle progression, angiogenesis, and metastatic activities in various cancers. The IGFs actions are mediated through the IGF-1 receptor that is involved in cell transformation induced by tumour. These effects depend on the bioavailability of IGFs, which is regulated by IGF binding proteins (IGFBPs). We describe here the role of the IGF system in cancer, proposing new strategies targeting this system. We have attempted to expand the general viewpoint on IGF-1R, its inhibitors, potential limitations of IGF-1R, antibodies and tyrosine kinase inhibitors, and IGFBP actions. This review discusses the emerging view that blocking IGF via IGFBP is a better option than blocking IGF receptors. This can lead to the development of novel cancer therapies.

Show MeSH

Related in: MedlinePlus

Various strategic approaches to targeting IGF-1R receptors. Small-molecule TKIs, inactivating anti-IGF-1R antibodies, reduction or elimination of IGF-1R, protein expression by blocking IGF-1R, transcription (with triple helix) or translation (antisense technology and siRNA), IGF-1R, and mutants lacking beta-subunits (dominant-negative receptors).
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4383470&req=5

fig7: Various strategic approaches to targeting IGF-1R receptors. Small-molecule TKIs, inactivating anti-IGF-1R antibodies, reduction or elimination of IGF-1R, protein expression by blocking IGF-1R, transcription (with triple helix) or translation (antisense technology and siRNA), IGF-1R, and mutants lacking beta-subunits (dominant-negative receptors).

Mentions: There are several approaches of targeting IGF-R till date, namely, small molecule tyrosine kinase inhibitors (TKIs), anti-IGF-1R antibodies, and molecular agents such as antisense and small interfering RNAs (si-RNAs) [107, 120] (Figure 7).


Insulin-like growth factor system in cancer: novel targeted therapies.

Brahmkhatri VP, Prasanna C, Atreya HS - Biomed Res Int (2015)

Various strategic approaches to targeting IGF-1R receptors. Small-molecule TKIs, inactivating anti-IGF-1R antibodies, reduction or elimination of IGF-1R, protein expression by blocking IGF-1R, transcription (with triple helix) or translation (antisense technology and siRNA), IGF-1R, and mutants lacking beta-subunits (dominant-negative receptors).
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4383470&req=5

fig7: Various strategic approaches to targeting IGF-1R receptors. Small-molecule TKIs, inactivating anti-IGF-1R antibodies, reduction or elimination of IGF-1R, protein expression by blocking IGF-1R, transcription (with triple helix) or translation (antisense technology and siRNA), IGF-1R, and mutants lacking beta-subunits (dominant-negative receptors).
Mentions: There are several approaches of targeting IGF-R till date, namely, small molecule tyrosine kinase inhibitors (TKIs), anti-IGF-1R antibodies, and molecular agents such as antisense and small interfering RNAs (si-RNAs) [107, 120] (Figure 7).

Bottom Line: These effects depend on the bioavailability of IGFs, which is regulated by IGF binding proteins (IGFBPs).We have attempted to expand the general viewpoint on IGF-1R, its inhibitors, potential limitations of IGF-1R, antibodies and tyrosine kinase inhibitors, and IGFBP actions.This can lead to the development of novel cancer therapies.

View Article: PubMed Central - PubMed

Affiliation: NMR Research Centre, Indian Institute of Science, Bangalore 560012, India.

ABSTRACT
Insulin-like growth factors (IGFs) are essential for growth and survival that suppress apoptosis and promote cell cycle progression, angiogenesis, and metastatic activities in various cancers. The IGFs actions are mediated through the IGF-1 receptor that is involved in cell transformation induced by tumour. These effects depend on the bioavailability of IGFs, which is regulated by IGF binding proteins (IGFBPs). We describe here the role of the IGF system in cancer, proposing new strategies targeting this system. We have attempted to expand the general viewpoint on IGF-1R, its inhibitors, potential limitations of IGF-1R, antibodies and tyrosine kinase inhibitors, and IGFBP actions. This review discusses the emerging view that blocking IGF via IGFBP is a better option than blocking IGF receptors. This can lead to the development of novel cancer therapies.

Show MeSH
Related in: MedlinePlus